clinical trial · NCT07284849
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
CRC (Colorectal Cancer)INCA33890PlaceboBevacizumabFOLFOX
brief summary
The purpose of this study is to evaluate the efficacy and safety of standard-of-care chemotherapy and bevacizumab with or without INCA33890 in the first-line treatment of metastatic microsatellite stable colorectal cancer.
started
Mar 5, 2026
primary completion
Dec 29, 2028
completion
Sep 28, 2029
last updated
Jun 30, 2026
official title
A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol